A review of cutaneous drug eruptions

Clinics in Geriatric Medicine

Volumn 29, Issue 2, 2013, Pages 527-545

  Ahmed, Ammar M ^a   Pritchard, Sarah ^b   Reichenberg, Jason ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Adverse cutaneous reaction; Drug eruption; Drug reaction

Indexed keywords

ACNE; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CAUSAL ATTRIBUTION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; DRUG ERUPTION; FIXED DRUG ERUPTION; HISTOPATHOLOGY; HUMAN; LEUKOCYTOCLASTIC VASCULITIS; LICHENOID ERUPTION; MEASLES LIKE RASH; PATHOPHYSIOLOGY; PATIENT CARE; PEMPHIGUS; PUSTULE; REVIEW; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIAL ERUPTION;

AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; HUMANS; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS;

EID: 84876346323     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2013.01.008     Document Type: Review

References (99)

1. Chan H.L., Stern R.S., Arndt K.A., et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reaction caused by drugs among outpatients. Arch Dermatol 1990, 126:43-47.
2. Yalcin B., Tamer E., Toy G.G., et al. The prevalence of skin disease in the elderly; analysis of 4099 geriatric patients. Int J Dermatol 2006, 45:672-676.
3. Carneiro S.C., Azevedo-e-Sailva M., Ramos-e-Silva M. Drug eruptions in the elderly. Clin Dermatol 2011, 29:43-48.
4. Routledge P.A., O'Mahony M.S., Woodhouse K.W. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004, 57:121-126.
5. Gandhi T.K., Weingart S.N., Borus J., et al. Adverse drug events in ambulatory care. N Engl J Med 2003, 348:1556-1564.
6. Hernandez-Salazar A., Rosales S.P., Rangel-Frausto S., et al. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006, 37:899-902.
7. Arndt K.A., Jick H. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1976, 235:918-923.
8. Bigy M., Jick S., Jick H., et al. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975-1982. JAMA 1986, 256:3358-3363.
9. Black A.J., Somers K. Drug-related illness resulting in hospital admission. J R Coll Physicians Lond 1984, 18:40-41.
10. Lakshmanan M.C., Hersey C.O., Breslan D. Hospital admissions caused by iatrogenic disease. Arch Intern Med 1986, 146:1931-1934.
11. Moore N., Lecointre D., Noblet C., et al. Frequency and cost of serious adverse drug reaction in a department of general medicine. Br J Clin Pharmacol 1998, 45:301-308.
12. Tangiisuran B., Wright J., Van Der Camen T., et al. Adverse drug reactions in elderly: challenges in identification and improving preventative strategies. Age Ageing 2009, 38(4):358-359.
13. International Drug Monitoring. The role of the hospital. World Health Organ Tech Rep Ser 1969, 425:5-24.
14. Beijer H.J., de Blaey C.J. Hospitalizations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002, 24:46-54.
15. Mannesse C.K., Derkx F.H., de Ridder M.A., et al. Contribution of adverse drug reaction to hospital admission of older patients. Age Ageing 2000, 29:35-39.
16. Shear N.H., Knowles S.R., Sullivan J.R., et al. Cutaneous reactions to drugs. Fitzpatrick's dermatology in general medicine 2003, 1330-1337. McGraw-Hill, New York. 6th edition. I.M. Freedburg, A.Z. Eisen, K. Wolff (Eds.).
17. Valeyrie-Allanore L., Sassolas B., Roujeau J.C. Drug-induced skin, nail, and hair disorders. Drug Saf 2007, 30:1011-1030.
18. Hunziker T., Kunzi U.P., Brunschweig S., et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20 year survey. Allergy 1997, 52:388-393.
19. Yawalkar N. Drug-induced exanthemas. Toxicology 2005, 209:131-134.
20. Lee A., Thomson J. Drug-induced skin reactions. Adverse drug reactions 2006, Pharmaceutical press, London, UK, p. 125-56. 2nd edition.
21. Bibgy M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001, 137:765-770.
22. Roujeau J.C. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005, 209:123-129.
23. Bronnimann M., Yawaker N. Histopathology of drug induced exanthems: is there a role in diagnosis of drug allergy?. Curr Opin Allergy Clin Immunol 2005, 5:317-321.
24. Justiniano H., Berlingeri-Ramous A.C., Sanchez J.L. Pattern analysis of drug induced skin diseases. Am J Dermatopathol 2008, 30:325-369.
25. Naim M., Weyers W., Metze D. Histopathologic features of exanthematous drug eruptions of the macular and papular type. Am J Dermatopathol 2011, 33(7):695-704.
26. Shin H.T., Chang M.W. Drug eruptions in children. Curr Probl Pediatr 2001, 31(7):207-234.
27. Souteyrand P., D'Incan M., Parent S. Misleading or rare cutaneous drug reactions. Rev Prat 2000, 50:1329-1333.
28. McKenna J., Leiferman K. Dermatologic drug reactions. Immunol Allergy Clin North Am 2004, 24:399-423.
29. Nigen S., Knowles S., Shear N. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003, 3:278-299.
30. Bircher A.J. Drug induced urticaria and angioedema caused by non-IgE mediated pathomechanisms. Eur J Dermatol 1999, 8:657-663.
31. Dykewicz M. Cough and angioedema for angiotension-converting enzyme inhibitors: no insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004, 4:267-270.
32. Kanji S., Chant C. Allergic and hypersensitivity reactions in the intensive care unit. Crit Care Med 2010, 38(6):s162-s168.
33. Helbling A., Hurni T., Mueller U.R., et al. Incidence of anaphylaxis with circulatory symptoms; a study over a 3 year period comprising 940,000 inhabitants of the Swiss Canton Ber. Clin Exp Allergy 2004, 34:285-290.
34. Park B.K., Kitteringham N.R., Powell H., et al. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 2000, 22(9):1173-1175.
35. Kearns G.L., Wheeler J.G., Childress S.H., et al. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994, 125:805-811.
36. Slama T. Serum Sickness-like illness associated with ciprofloxacin. Antimicrobial Agents Chemother 1990, 34(5):904-905.
37. Carlson J.A., Ng B.T., Chen K.R. Cutaenous vaculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 2005, 27:504-528.
38. Bahrami S., Malone J.C., Webb K.G., et al. Tissue eosinophilia as an indicator of drug induced cutaneous small vessel vasculitis. Arch Dermatol 2006, 142:155-161.
39. Roujeau J.C., Stern R.S. Severe cutaneous adverse reaction to drugs. N Engl J Med 1994, 331:1272-1285.
40. Garcia-Porrua C., Llorca J., Gonzales-Louzao C., et al. Hypersensitivity vasculitis in adults: a benign disease usually limited to skin. Clin Exp Rheumatol 2001, 19:85-88.
41. Cuellar M.L. Drug-induced vasculitis. Curr Rheumatol Rep 2002, 4:55-59.
42. Calabrese L.H., Duna G.F. Drug-induced vasculitis. Curr Opin Rheumatol 1996, 8:34.
43. Callen J.P., af Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J 1987, 80(7):848-851.
44. Sullivan T.P., King L.E., Boyd A.S. Colchicine in dermatology. J Am Acad Dermatol 1998, 39(6):993-999.
45. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009, 9:316-321.
46. Crowson A.N., Brown T.J., Magro C.M. Progress in the understanding of the pathology and pathogeneis of cutaneous drug eruptions. Am J Clin Dermatol 2003, 4:407-428.
47. Zurier R.B., Hoffstein S., Weissmann G. Mechanisms of lysosomal enzyme release from human leukocytes. J Cell Biol 1973, 58:27-41.
48. Kanzaki T. Acneiform eruption induced by Lithium carbonate. J Dermatol 1991, 18:481-483.
49. Kunzle N., Venetz J.P., Pascual M., et al. Sirolimus-induced acneiform eruption. Dermatology 2005, 211:366-369.
50. Rothstein G., Clarkson D.R., Larsen W., et al. Effect of lithum on neutrophil mass and production. N Engl J Med 1978, 298:178-180.
51. Galimont-Collen A.F., Vos L.E., Lavrijsen A.P., et al. Classification and management of skin, hair, nail, and mucosal side effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007, 43:845-851.
52. Wu P., Balagula Y., Lacouture M., et al. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol 2011, 23:343-351.
53. Journagan S., Obadiah J. An acneiform eruption due to erlotinib: prognostic implication and management. J Am Acad Dermatol 2006, 54:358-360.
54. Gupta A.K., Knowles S.R., Gupta M.A., et al. Lithium therapy associated with hidradenitis suppurativa: case report and a review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995, 32:382-386.
55. Sidoroff A., Halevy A., Bavinck J.N., et al. Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J Cutan Pathol 2001, 28:113-119.
56. Mengesha Y., Bennett M. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol 2002, 3:389-400.
57. Roujeau J.C., Bioulac-Sage P., Bourseau C., et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991, 127:1333-1338.
58. Burrows N.P., Russell Jones R.R. Pustular drug eruptions: a histopathological spectrum. Histopathology 1993, 522:569.
59. Wolkenstein P., Chosidow O., Flechet M.I., et al. Patch testing in severe cutaneous adverse drug reactions, including Steven Johnson syndrome, and toxic epidermal necrolysis. Contact Derm 1996, 35:234.
60. Ruocco V., Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. J Dermatol 1991, 30(5):307-312.
61. Brenner S., Bialy-Golan A., Anhalt G.J. Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 1997, 36(6 Pt 1):919-923.
62. Wakelin S.H., Allen J., Zhou S., et al. Drug-induced linear IgA disease with antibodies to collagen VII. Br J Dermatol 1998, 138(2):310-314.
63. Pisani M., Ruocco V. Drug-induced pemphigus. Clin Dermatol 1986, 4(1):118-132.
64. Brenner S., Bialy-Golan A., Ruocco V. Drug-induced pemphigus. Clin Dermatol 1998, 16:393-397.
65. Kaplan R.P., Potter T.S., Fox J.N. Drug-induced pemphigus related to angiotension-converting enzyme inhibitors. J Am Acad Dermatol 1992, 26:364-366.
66. De Angelis E., Lormbardi M.L., Grassi M., et al. Enalapril: a powerful in vitro non-thiol ancantholytic agent. Int J Dermatol 1992, 31(10):722-724.
67. Smith E.P., Taylor T.B., Meyer L.J., et al. Antigen identification in drug-induced bullous pemphigiod: three case reports and literature review. Mayo Clin Proc 1994, 69(12):1166-1171.
68. Paul C., Wolkenstein P., Prost C., et al. Drug-induced linear IgA disease with antibodies to collagen VII. Br J Dermatol 1997, 136(3):406-411.
69. Tilly J.J., Drolet B., Esterly N. Lichenoid eruptions in children. J Am Acad Dermatol 2004, 51:606-624.
70. Eligehausen P., Elsner P., Burg G. Drug-induced lichen planus. Clin Dermatol 1998, 16:325-332.
71. Penneys N.S., Ackerman A.B., Gottlieb N.L. Gold dermatitis. Arch Dermatol 1974, 109:372-376.
72. Hofmann C., Burg G., Jung C. Kutane Nebenwirkungen der Gold therapie: Klinische und histologische Ergebnisse. Z Rheumatol 1986, 45:100-106.
73. Nguyen D., Wittich C. Metoprolol-induced lichenoid dermatitis. J Gen Intern Med 2011, 26(11):1379-1380.
74. Ackerman A.B. Superficial perivascular dermatitis. Histologic diagnosis of inflammatory skin diseases: a method by pattern analysis 1987, 210-211. Lea & Febiger, Philadelphia. A.B. Ackerman (Ed.).
75. Penneys N.S. Gold therapy: dermatologic uses and toxicities. J Am Acad Dermatol 1979, 1:315-320.
76. Heymann W., Lerman J., Luftschein S. Naproxen-induced lichen planus. J Am Acad Dermatol 1984, 10:299-301.
77. Taylor A.E., Hindson C., Wacks H. A drug-eruption due to acebutolol with combined lichenoid lupus erythematosus features. Clin Exp Dermatol 1982, 7:219-221.
78. Burry J.N., Kirk J. Lichenoid drug reaction from methyldopa. Br J Dermatol 1974, 91:475-476.
79. Srebrnik A., Bar-Nathan E., Ilie B., et al. Vaginal ulcerations due to lithium carbonate therapy. Cutis 1991, 67:41-44.
80. Hogan D., Burgess W., Epstein J., et al. Lichenoid stomatitis associated with lithium carbonate. J Am Acad Dermatol 1985, 13:243-246.
81. Barvaliya M., Sanmukhani J., Patel T., et al. Drug-Induced Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med 2011, 57:115-119.
82. Borchers A.T., Lee J.L., Nagua S.M., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008, 7:598-605.
83. Li L.F., Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district in China. Clin Exp Dermatol 2006, 31:642-647.
84. Yang C.Y., Dao R.L., Lee T.H., et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology 2011, 77:2025-2033.
85. Di Pascuale M.A., Espana E.M., Liu D.T., et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnsons syndrome and toxic epidermal necrolysis sysndrome. Ophthalmology 2005, 112:904-912.
86. Sharma V.K., Sethuraman G. Adverse cutaneous reactions to drugs: an overview. J Postgrad Med 1996, 42:15-22.
87. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostic and therapy. J Dtsch Dermatol Ges 2009, 7:142-160.
88. Rzany B., Hering O., Mockenhaupt M., et al. Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Br J Dermatol 1996, 135(1):6-11.
89. Kardaun S.H., Jonkman M.F. Dexamethasone pulse therapy for Steven-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007, 87:144-148.
90. Fiszenson-Albala F., Auzerie V., Mahe E., et al. A 6-month prospective survery of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003, 149:1018-1022.
91. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., et al. Variability in the clinical pattern of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol 2007, 156:609.
92. Ganeva M., Gancheva T., Lazarova R., et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 2008, 47:853.
93. Eshki M., Allanore L., Musette P., et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009, 145:67.
94. Zaccara G., Franciotta D., Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007, 48:1223.
95. Bachot N., Roujeau J.C. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003, 4(8):561-572.
96. Cacoab P., Musette P., Descamps V., et al. The DRESS syndrome: a literature review. Am J Med 2011, 124:588-597.
97. Descamps V., Valance A., Edlinger C., et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001, 137:301-304.
98. Ichiche M., Kiesche N., De Bels D. DRESS syndrome associated with HHV-6 reactivation. Eur J Intern Med 2003, 14:498-500.
99. Bohan K.H., Mansuri T.F., Wilson N.M. Anticonvulsant hypersensitivity syndrome: implication for pharmaceutical care. Pharmacotherapy 2007, 27:1425.